Last updated: 2026-09-16 09:45:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Arcutis Biotherapeutics, Inc. (ARQT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $23,44, with a market capitalisation of $3,05B and a P/E ratio of 103,62. Over the past 52 weeks, its price has ranged from $16,57 to $31,77. This page covers its latest market performance, valuation, price trends and company information.
$3,05B | |
$23,52 | |
$40,88 | |
$1,76 | |
$23,51 | |
768,00 | |
1,77M | |
103,62 | |
$31,77 | |
$16,57 | |
-- | |
-- |
Arcutis Biotherapeutics, Inc. (ARQT) is trading at $23,44 in pre-market trading as of 2026-09-16 08:56:00, down 0,30% ($0,07) from the previous close of $23,51
Pre-market trading shows how investors are pricing ARQT before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Arcutis Biotherapeutics, Inc. (ARQT) moved from $23,90 to $23,44, representing a decline of 1,93% ($0,46).
The stock traded between $22,91 and $25,13 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 2,55 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 45,2%
ARQT is currently trading at $23,44, placing it 45,2% of the way from its 52-week low of $16,57 to its 52-week high of $31,77. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 354 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Arcutis Biotherapeutics, Inc. (ARQT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.